VIDEO: Trial helps inform treatment sequencing in EGFR-mutated lung cancer
Click Here to Manage Email Alerts
Healio spoke with Charu Aggarwal, MD, MPH, about data from the Keynote-789 trial presented at this year’s ASCO Annual Meeting.
The trial was a randomized, double-blind, phase 3 study of pemetrexed and platinum-based chemotherapy with or without pembrolizumab as a subsequent therapy in patients with TKI-resistant, EGFR-mutation positive non-small cell lung cancer.
Aggarwal, who is the Lesley M. Heisler assistant professor for lung cancer excellence at University of Pennsylvania's Perelman School of Medicine and a HemOnc Today Editorial Board Member, explained that the trial “affirms the practice” of the use of chemotherapy in osimertinib-resistant EGFR-mutated NSCLC.
It also shows that immunotherapy may not always be beneficial in this patient population, according to Aggarwal.
“I do think that this will define our practice in the future,” she said. “This is a good trial; I think it had to be done in a prospective fashion, and will really help us also sequence therapies for these patients with EGFR mutation-positive lung cancer.”
Reference:
- Yang JCH, et al. Abstract LBA9000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Healio Interview
Read more about
Click Here to Manage Email Alerts